KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges

KRAS is the most frequently mutated oncogene identified in human cancers. Despite the numerous efforts to develop effective specific inhibitors against KRAS, this molecule has remained “undruggable” for decades. The development of direct KRAS inhibitors, such as sotorasib, the first FDA-approved dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceddia, Serena, Landi, Lorenza, Cappuzzo, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408881/
https://www.ncbi.nlm.nih.gov/pubmed/36012655
http://dx.doi.org/10.3390/ijms23169391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408881/
https://www.ncbi.nlm.nih.gov/pubmed/36012655
http://dx.doi.org/10.3390/ijms23169391

Ejemplares similares